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Vertebrates, as well as invertebrates and plants, have devel-
oped mechanisms to detect and respond to intruders (31, 56).
Clearly, inflammation and innate and adaptive immune re-
sponses are aimed at destroying the intruders. Gram-negative
bacteria contain lipopolysaccharides (LPS) in their outer mem-
branes (82). LPS, which has been studied extensively, is con-
sidered the prototypic activator of innate immunity. Picomolar
concentrations of LPS are sufficient to stimulate cells of the
immune, inflammatory, and vascular systems (81). LPS belongs
to the group of molecules produced by pathogens and contain-
ing so-called pathogen-associated molecular patterns
(PAMPs). PAMPs are recognized by one or more members of
a family of transmembrane signaling receptors known as the
Toll-like receptor (TLR) family, as well as by intracellular
PAMP-detecting molecules, such as nucleotide-binding oli-
gomerization domain 1 (Nod-1), Nod-2, and retinoic acid in-
ducible gene I (RIG-I) (11, 23, 79, 91). To date, 13 different
mammalian TLRs have been identified and cloned (77). Acti-
vation of TLRs induces intracellular signaling pathways that
lead to the production of specific sets of proinflammatory cy-
tokines and chemokines, as well as type I interferons (IFNs)
and IFN-inducible gene products (1).
IFN was discovered about 50 years ago as a soluble factor
that inhibited viral replication upon induction of specific anti-
viral genes, such as Oas and Mx, in infected cells. The IFNs
were initially classified as classical or type I IFNs and immune
or type II IFNs. Type I IFNs consist of multiple alpha IFN
(IFN-) proteins, and single IFN-, -ε, -, - (also called lim-
itin), and - subtypes, as well as the  and  subtypes found in
pigs and sheep, respectively (61). IFN-	1 (interleukin-29 [IL-
29]), IFN-	2 (IL-28A), and IFN-	3 (IL-28B) function some-
what like type I IFN but belong to a new cytokine family (44).
Type II IFN consists of a single gene that codes for the cyto-
kine IFN-
.
The last few years of research have not only led to a much
better characterization of the classical antiviral activities of
IFN but have also revealed a number of other biologically
important immune regulatory functions of type I IFNs. To-
gether, these results led to the conclusion that type I IFNs are
essential links between the early innate responses and the
subsequent, more specific adaptive immune responses (7, 38).
Type I IFNs induce major histocompatibility complex class I
expression and have important effects on the maturation and
function of dendritic cells (DCs). These IFNs also lead to
amplification of their own induction, as well as that of IL-15
and a high-affinity form of the IL-12 receptor, and activate
natural killer (NK) cell cytotoxicity (30, 33, 55, 69, 88). Indeed,
recent studies have shown that a clear connection exists be-
tween type I IFN and antigen-presenting DCs at two levels.
First, a specific DC precursor, the plasmacytoid pre-DC (p-
preDC), was identified as a cell type that, after stimulation with
infectious agents, can secrete very large amounts of type I
IFNs. Second, type I IFNs have been shown to act as differ-
entiation and maturation factors for DCs. The signal for the
upregulation of costimulatory surface molecules, including
CD40, CD80 (B7-1), and CD86 (B7-2), is initiated by LPS, but
it is mediated by the IFN- and the type I interferon receptor
(IFNAR) signaling axis (30). Furthermore, type I IFNs are
crucial in inducing cytotoxic activity and the proliferation of
NK cells (55) and may also play key roles in the induction of
effective B-cell responses (10).
In addition, not all cell types express type I IFN, and differ-
ent cell types also use different molecules to induce the pro-
duction of type I IFN. Using IRF-7-knockout mice, it was
demonstrated that IRF-7 is important in type I IFN induction
after virus-activated MyD88-independent signaling, as well as
in TLR9-induced MyD88-dependent signaling in DCs (21).
Spatiotemporal regulation of MyD88-IRF-7 signaling is critical
for type I IFN induction in response to TLR9 activation in
pDCs. In cDCs, CpG-A localizes to lysosomes and is unable to
induce IFN (32). It also seems that in monocytes no IFN- is
induced after LPS stimulation (8, 26). Also, in contrast to
peritoneal macrophages, alveolar macrophages do not produce
bioactive IFN- after TLR3 and TLR4 stimulation (64).
Taken together, the available data suggest that type I IFNs
serve as a link between the innate immune response to infec-
tion and the adaptive immune response.
In this review, we discuss the importance of type I IFNs in
LPS-induced lethal endotoxemia and sepsis, and the rationale
for treating endotoxemia in animal models and sepsis in hu-
man patients by blocking type I IFN production or activity.
TLR4-MEDIATED TYPE I IFN PRODUCTION
Bacterial LPS is an important structural component of the
outer membrane of gram-negative bacteria. It is considered the
principal active agent in the pathogenesis resulting from infec-
tion with gram-negative bacteria. Indeed, the injection of LPS
leads to endotoxemia and endotoxic shock, which closely re-
semble sepsis and septic shock (6). We briefly review below the
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major factors involved in the induction of type I IFNs after
LPS stimulation and describe the major factors involved in
responding to these IFNs.
Beutler and coworkers (63) and Qureshi et al. (65) demon-
strated that the genetic defects in two LPS hyporesponsive
strains of mice are linked to TLR4. C3H/HeJ mice have a point
mutation in the coding region of the Tlr4 gene, resulting in the
substitution of a highly conserved proline at codon 712 by
histidine, whereas in C57BL/10ScCr mice the Tlr4 gene is de-
leted. These mutations render these strains resistant to endo-
toxin (63). Also, C3H/HeJ mice showed enhanced susceptibil-
ity to infection by gram-negative bacteria (e.g., Salmonella
enterica serovar Typhimurium), indicating that recognition of
LPS is essential for clearing the infection (21, 57). It has been
demonstrated that the activation of macrophages by LPS re-
sults in the release of a variety of inflammatory cytokines, such
as tumor necrosis factor (TNF), IL-1, IL-6, IL-8, IL-12, and
IFN-, in addition to smaller mediators such as prostaglandins
and nitric oxide (NO) (76). Indeed, it has been shown that
peritoneal macrophages of TLR4 knockout mice do not pro-
duce any detectable levels of TNF- and IL-6 (80).
After binding to LPS, TLR4 dimerizes and undergoes a
conformational change required for the recruitment of down-
stream Toll/interleukin-1 receptor (TIR) domain-containing
adaptor molecules (Fig. 1). These include the myeloid differ-
entiation primary-response protein 88 (MyD88), the TIR-do-
main-containing adaptor protein, the TRIF-related adaptor
molecule (TRAM), and the TIR-domain-containing adaptor
protein inducing IFN- (TRIF), which together determine the
signaling specificity of the response (1). All TLRs, except
TLR3, recruit MyD88 in order to activate both NF-B and the
mitogen-activated protein kinases (MAPKs), such as extracel-
lular signal-regulated kinase (ERK), p38, and c-Jun N-terminal
kinase (JNK) (1). MyD88 recruits IL-1 receptor-associated
kinases through interaction of the death domains. IL-1 recep-
tor-associated kinases are activated by phosphorylation, after
which they associate with TRAF6, leading to activation of the
IB kinase (IKK) complex, the degradation of IB, the nuclear
translocation of NF-B, and the expression of inflammatory
cytokines (78, 79).
Stimulation with LPS also leads to the recruitment of TRIF
to the TLR4 receptor complex and consequently to activation
of IFN-regulatory factor 3 (IRF-3). This transcription factor
induces the expression of the gene encoding IFN- (1). Hiscott
FIG. 1. Representation of TLR4-signaling through the MyD88-dependent and MyD88-independent pathways. The MyD88-independent/
TRIF-dependent pathway leads to the induction of IFN-. IFN- then binds to the IFNAR complex in an autocrine or paracrine way, leading to
activation of ISGF3 and AAF. The former binds to IFN-stimulated response elements of IFN-inducible genes, such as those encoding IRF-7, OAS,
and PKR. IRF-7 can bind to promoter elements of the genes encoding IFN- and IFN-. The molecules highlighted in yellow are those whose
deletion in mice leads to resistance to endotoxemia.
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and coworkers identified the kinases responsible for activation
of IRF-3. Using two-hybrid screening, they found that IRF-3
was associated with two IKKs (28, 71), namely, TANK-binding
kinase 1 (TBK1) and IKK-ε/IKK-, whose activities are distinct
from those of the canonical IKK- and IKK (79). Mouse em-
bryonic fibroblasts (MEFs) derived from TBK1-deficient
(TBK1/) mice are impaired in the production of type I IFNs
and IFN-inducible gene products in response to LPS but not in
the production of proinflammatory cytokines (Table 1) (51).
IKK-ε/ mice show normal expression of these genes, but
MEFs from IKK-ε/TBK1 double-deficient mice, upon specific
TLR3 stimulation with poly(I:C), were unable to produce
IFN- and IFN-inducible proteins (note that the TLR3 recep-
tor does not use the MyD88 pathway but only the TRIF path-
way). Moreover, in IKK-ε/TBK1 double-deficient cells, LPS
failed to activate IRF-3 (27). It was also shown that after TLR4
stimulation TRIF can recruit TRAF6-TAK1-TAB2 via its
TRAF6-binding site, which is different from its IRF-3 activat-
ing site (52). Upon LPS stimulation, phosphorylated IRF-3
dimerizes and translocates to the nucleus. IRF-3 dimers be-
come transcriptionally active after association with p300/CBP
coactivators. Activated IRF-3, along with NF-B, induces the
expression of the IFN- gene (86).
JAK-STAT PATHWAY
Once produced, type I IFNs bind to a receptor complex
consisting of two subunits, IFNAR1 and IFNAR2, termed the
IFNAR complex. Stimulation of the IFNAR complex initiates
a signaling cascade mediated by the tyrosine kinases janus
kinase (JAK) 1 and tyrosine kinase (TYK) 2, which activate the
signal transducer and activator of transcription 1 (STAT1) and
STAT2 to form a STAT1/STAT2 heterodimer (13). Other
pathways, most notably the p38 MAPK and phosphatidylino-
sitol 3-kinase (PI3K) pathways, are also induced (62). STAT1/
STAT2 complexes associate with a p48 protein, identified as
IRF-9, to form the IFN-stimulated gene factor 3 (ISGF3). This
factor recognizes IFN-stimulated response elements in pro-
moter regions of IFN-responsive genes (ISGs) encoding pro-
teins such as PKR (double-stranded RNA-dependent protein
kinase), OAS (2,5-oligoadenylate synthetase), Mx1 (myxovi-
rus [influenza] resistance 1), and IRF-7 (13). In addition to
being part of ISGF3, STAT1 also forms homodimers that bind
to a distinct promoter element, the IFN-
-activated site
(GAS). STAT1 homodimers, called the AAF (IFN- activated
factor) complex, induce the IRF-1 gene, another transcrip-
tional activator (41, 42). When IRF-7 is induced by ISGF3, it
becomes phosphorylated and is translocated to the nucleus (3),
where it activates the IFN-/ promoters (49, 69). The induc-
tion of serum IFN-/ by viruses is severely impaired in IRF-7
knockout mice, which shows that IRF-7 is essential for the
induction of type I IFN after virus infection (34). IFN-/ gene
induction is more severely impaired by blocking IRF-7 expres-
sion than by introducing an IRF-3-null mutation (25). Thus,
IRF-7 plays a crucial role in the massive IFN-/ production
through a positive feedback loop (see Fig. 1) (3, 69, 70).
The JAK-STAT pathway is negatively regulated by distinct
regulatory proteins, including the suppressors of cytokine sig-
naling, SOCS-1 and SOCS-3, which inhibit the kinase activity
of JAK1. STAT1 tyrosine phosphorylation after TLR trigger-
ing is severely impaired by SOCS-1 and, to a lesser extent, by
SOCS-3. Thus, SOCS proteins, which can be induced by cyto-
kines, as well as by TLR ligands such as LPS and CpG, limit the
extent of TLR signaling by inhibiting the type I IFN signaling
pathway (4). Recent data illustrate that SOCS-1 is also able to
inhibit the activity of Mal, one of the four TLR adaptor mol-
ecules (48a).
JAK1 phosphorylation is also negatively regulated by pro-
tein tyrosine phosphatases (PTPs), such as SRC homology 2
(SH2)-domain-containing PTP1 (SHP1), SHP2, CD45, and T-
cell PTP (TCPTP) (72).
STAT1 is not only regulated by the PTPs SHP2 and TCPTP
but also by protein inhibitor of activated STAT (PIAS).
STAT1-mediated gene activation is regulated by PIAS1 and
protein inhibitor of activated STAT y. PIAS1 blocks the DNA-
binding activity of STAT dimers and inhibits STAT1-mediated
gene activation in response to IFN-
 (47). Protein inhibitor of
activated STAT y acts as a transcriptional corepressor of STAT
by recruiting corepressor proteins such as histone deacetylase
(46).
SH2-containing inositol 5-phosphatase (SHIP) is a negative
regulator of the PI3K-pathway. The PI3K pathway stimulates a
number of other pathways, including the MyD88-dependent
(45) and the TRIF-dependent (87) pathways. Phosphorylation
of STAT1 has recently been shown to be PI3K dependent (66).
IFN- AS A CRITICAL MEDIATOR IN
LETHAL ENDOTOXEMIA
Type I IFNs have long been known to be potent antiviral
molecules. In the last few years, however, a critical role for
these IFNs in LPS-induced endotoxemia has been elucidated.
It has become clear that nonviral PAMPs, such as LPS, induce
the expression of type I IFN genes. The essential molecules
involved in inducing type I IFNs and in responding to them
have also become known. The role of these molecules in en-
TABLE 1. Summary of the biological effects, relevant to endotoxemia,
observed in mice or cells deficient in genes that are centrally
involved in induction of type I IFNs, downstream
signaling molecules, or IFNs themselvesa
Gene
KO/
LPS stimulation
Lethality Reference
Induction of
IFN- or IFN-
dependent
genes (mRNA
level)
Proinflammatory
cytokine
production
(protein level) or
NF-B activation
TRIF(m) 22 22 R 30
TRIF (c) 22 22 ND 89
TRAM (c) 22 22 ND 90
TBK1 (c) 22  (NF-B) ND 60
IKK-ε/ (c) 22 ND ND 27
IRF-3 22  (mRNA level) R 67
IFNAR1 ND ND R 36
TYK2 22  (IB degrad.) R 39
STAT1 22 ND R () 39
STAT2 ND ND ND 58
IFN- ND  R 39
SOCS-1 ND  (IB degrad.) S 22
a22, strongly decreased protein/mRNA level; , inflammatory cytokine pro-
duction normal; R, resistant to LPS; S, sensitive to LPS; m, mice; c, cells; ND, not
done.
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dotoxemia, as well as that of the IFNs themselves, is now being
investigated in knockout mice and in cells. Table 1 lists the
phenotypes relevant to this review. Figure 1 depicts molecules
whose knockout affects LPS responsiveness.
The most solid evidence that type I IFNs are central medi-
ators in endotoxemia was provided by Karaghiosoff et al., who
showed that IFN- knockout mice are resistant to lethal en-
dotoxemia induced by high doses of LPS and that they have
less serum TNF, NO, and IFN-
 after LPS challenge than
wild-type animals (39).
IFNAR1/ mice are highly susceptible to viral infection. In
cells from these mice, no signaling in response to type I IFN
was detectable, as measured by the induction of OAS. Also,
bone marrow macrophages from IFNAR1/ mice respond
abnormally to LPS (36). We indeed found that IFNAR1-defi-
cient mice completely resist LPS-induced lethal endotoxemia
(48). In addition, using macrophages from IFNAR1/ mice,
Vadiveloo et al. found that type I IFNs mediate the induction
of cyclin D2 by LPS (83).
A mutant mouse, called Lps2 and generated by random
mutagenesis with ENU in the laboratory of B. Beutler, appears
to contain a distal frameshift error in a TIR adaptor protein,
now known as TRIF or TICAM-1. TrifLps2 homozygote mice
are markedly resistant to endotoxemia and fail to produce type
I IFNs in response to LPS. LPS-induced STAT1 phosphoryla-
tion and IRF-3 dimerization are also impaired in these mice
(29). TRIF-deficient mice, generated in the laboratory of S.
Akira, are also defective in TLR4- and TLR3-induced expres-
sion of IFN- and activation of IRF-3. Furthermore, TRIF-
deficient macrophages are impaired in the production of in-
flammatory cytokines in response to the TLR4 ligand but not
in response to ligands of TLR2, TLR7, and TLR9. Also, poly(I:
C)-induced NF-B activation is severely impaired. In contrast,
the induction of NF-B and MAPK JNK by LPS is almost
normal. This might be due to an intact MyD88-dependent
early NF-B activation (89).
TRAM-deficient mice, also generated by S. Akira and co-
workers, are defective in LPS-induced cytokine production
(TNF- and IL-6). In TRAM-deficient macrophages (90) LPS
failed to induce IFN-- and IFN-stimulated genes (Ifit2,
Cxcl10, and Ccl5) and to activate STAT1.
TBK1 deficiency resulted in TNF-mediated liver degenera-
tion and consequent embryonic mortality (9). In TBK1/
macrophages, the LPS-induced activation of IRF-3 and STAT1
was absent or greatly diminished. Also, in response to LPS,
TBK1/ macrophages failed to upregulate the transcription
of IFN-- and IFN-mediated transcription of genes encoding
CXCL10, CCL5, IFN-5, IRF-7, IL-15, and Mx1. However,
NF-B activation and the induction of the NF-B-regulated
genes ICAM-1 and IB were normal in response to LPS (60).
Embryonic fibroblasts from IKK-ε/ mice responded nor-
mally to LPS with respect to IRF-3 activation and the induc-
tion of type I IFN. However, the expression of IRG-1 and
CXCL10 mRNA in IKK-ε/TBK1/ cells was severely im-
paired, and the induction of IFN-, IFN-, and ISG54 mRNA
after stimulation with poly(I:C) was abolished (27).
It was also shown recently, using IRF-3 knockout mice, that
IRF-3 is indeed essential for LPS-mediated IFN- gene induc-
tion. Loss of IRF-3 also affects the expression profile of other
genes, such as some IFN- subtypes, CXCL10, and IL-15. As
would be expected, IRF-3-deficient mice are resistant to LPS-
induced endotoxic shock (67).
As described above, the JAK-STAT pathway is involved in
the transduction of the signal induced by the IFNAR1 and
leading to expression of IFN-responsive genes, as well as the
massive upregulation of IFN-/ genes. The absence of several
molecules of the JAK-STAT pathway causes resistance to LPS-
induced endotoxemia. In addition, overexpression of negative
regulators of the JAK-STAT pathway (see above) can shut
down IFN signaling and hence are expected to protect against
endotoxemia.
Tyk2 knockout mice are resistant to shock induced by high
doses of LPS. The induction of IL-1, IL-6, IL-12, TNF, and
NO in serum were comparable in wild-type and Tyk2-null
mice. LPS-induced MyD88-dependent signaling in vitro was
intact, as shown by the normal secretion of TNF, the degrada-
tion of IB, and the phosphorylation of p38, ERK1/2, and
JNK. In Tyk2-null macrophages, LPS-induced expression of
IFN- and IFN-4 mRNA was diminished, and the induction
of IFN
 mRNA was low. Moreover, the phosphorylation of
IRF-3 was normal, but the induction of IRF-1 and IRF-7
mRNA was reduced (39).
Mice defective in STAT1 are resistant to LPS, but not as
much as Tyk2 knockout mice. As would be expected, LPS-
induced expression of IFN- mRNA was reduced in the ab-
sence of STAT1. However, in contrast to Tyk2-null macro-
phages, STAT1-null macrophages were not impaired in IFN-

expression (39).
STAT2-null mice also showed a loss of the type I IFN au-
tocrine/paracrine loop, which affects several aspects of the
immune response (58). Furthermore, it was shown in IRF-7
knockout mice that the transcription factor IRF-7 is essential
for the induction of IFN/ genes after virus infection (34).
Deficiency in SOCS-1 leads to early-onset fatal disease. Ex-
periments on cells from SOCS-1 knockout mice demonstrated
that SOCS-1 is necessary for the inhibition of IFN-/ receptor
signaling through effects on Tyk2. As expected, SOCS-1/
mice did not resist LPS, nor did SOCS1/ IFN-
/ mice
(22). On the contrary, SOCS-1 is strongly induced by LPS and
is an essential protective molecule, because SOCS-1/ mice
were found to be supersensitive to LPS (43, 54). Moreover,
SOCS-1/ mice develop severe inflammatory disease, which
appears to result solely from overactivity of the type I IFN
signaling cascade and not from enhanced type II IFN activity
(18). The overexpression of SOCS-1 or SOCS-3 downregulated
the IFN-induced phosphorylation of STAT1 and STAT3. The
overexpression of SOCS-1 in cells abolished the mRNA ex-
pression of both OAS and Mx1, and the overexpression of
SOCS-3 inhibited mainly OAS mRNA expression. Thus,
SOCS-1 and SOCS-3 have important negative regulatory ef-
fects on the type I IFN-induced activation of the JAK-STAT
pathway (85). For example, in macrophages overexpressing
SOCS-1 or SOCS-3, induction of the IFN--dependent gene
CXCL10 was defective, and LPS-induced STAT1 phosphory-
lation was abolished (4). Interestingly, recent data indicate that
protein therapy using cell-permeable SOCS-3 has a curative
effect in mouse models of endotoxemia (37).
Not much is known about the potential role of the other
JAK-STAT inhibitory molecules SHP1, SHP2, CD45, and
TCPTP; the PIAS proteins; and SHIP in endotoxemia. It was
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shown that SHIP/ macrophages are hyper-responsive to
LPS, that they are not endotoxin tolerant, and that their
STAT1 phosphorylation is not diminished after a second ex-
posure to LPS (73). It is clear, however, that SHIP and PTEN
proteins are very potent regulators of the TLR4 signaling path-
way (10a, 17a).
IFN-/ AS A THERAPEUTIC TOOL AND TARGET
Almost 50 years of intense research have made it clear
that type I IFNs are absolutely essential in the defense of
vertebrates against many viruses. First, the IFN genes are
strongly conserved, and their orthologues have been found
in different species, e.g., fish and birds. Second, deficiency of
IFN receptor genes leads to dramatically increased sensitiv-
ity for many viruses (36, 53). Third, exogenously added IFNs
have antiviral effects, such as the curative effects on hepatitis
C-infected patients (59). However, type I IFNs are also
important in controlling other diseases and pathologies. In
leishmaniasis, low doses of IFN- protect mice from pro-
gressive cutaneous and fatal visceral disease after infection
with Leishmania major parasites (50). Also, IFN- is the
most commonly used therapy for relapsing multiple sclerosis
(24), and it can also inhibit collagen-induced arthritis in
mice (84). Finally, type I IFNs inhibit the proliferation of
several human cancers, a therapy that has been evaluated in
clinical trials, e.g., for renal cancer (14, 40, 68). Based on
these findings, one can conclude that type I IFNs are essen-
tial and that they should be given to patients under certain
pathological conditions.
It is now also clear that resistance to endotoxemia can be
induced by deletion of genes encoding IFN-, IFNAR1, Tyk2,
or other genes involved in the induction of, or in the response
to, type I IFNs. The data support the idea that type I IFNs
should be considered as mediators in endotoxemia, although
the mechanism by which they mediate the toxic effects of LPS
is still an open question. However, several studies have clearly
shown that type I IFNs can induce the expression of genes
encoding other inflammatory molecules, such as NF-IL-6 and
many chemokines (12, 15, 48). Chemokines may orchestrate
cell migration, which, in collaboration with cytokines and other
inflammatory products, can lead to organ damage. Thus, ex-
cessive expression of IFN- could probably lead to organ dam-
age (Fig. 2), and blocking type I IFNs or their upstream or
downstream mediators could be an option. A recent study
clearly shows that this concept could be used in the treatment
of endotoxemia in experimental animals (37). Two central
questions, however, need to be addressed.
First, to what extent will an inhibitory molecule, such as a
FIG. 2. Contribution of IFN- in endotoxemia. IFN- is produced by macrophages and induces the expression of several genes, especially
chemokines, but also other cytokines. Excessive production of IFN- may lead to organ damage by overstimulating the production of chemokines
that may orchestrate cell migration, which, in collaboration with cytokines and other inflammatory products, can lead to organ damage.
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neutralizing antibody to IFN- or an IFNAR1 antagonist,
compromise the organism’s ability to combat viruses and/or
bacteria? Studies using IFNAR1-knockout mice indeed indi-
cate that these mice may be resistant to endotoxemia (48) but
supersensitive to viral infections (53). Further studies with
experimental animals or clinical trials are needed to answer
this first question. Indeed, we have to keep in mind that various
clinical trials aimed at blocking proinflammatory cytokines
such as IL-1 or TNF, which are elevated in sepsis, have failed.
For example, studies using TNF- or TNF receptor-deficient
mice have confirmed that TNF is a good marker but that it is
functionally inert during endotoxemia in mice, since these
knockout mice were neither protected nor sensitized during
endotoxemia (1a). Furthermore, in the absence of these cyto-
kines, animals may become unable to clear live bacteria and
more susceptible to infection. The finding that a certain cyto-
kine knockout mouse strain is protected against LPS may mean
that this cytokine is a mediator in endotoxemia but that it may
very well form part of a protective network against infection
with gram-negative bacteria. For example, IFN-
 receptor
knockout mice have proven to be extremely susceptible to
BCG, and treatment with infliximab sensitizes for Mycobacte-
rium tuberculosis (17). However, some possibilities can be con-
templated. First, e.g., in the case of the IFNAR1, it would be
interesting to investigate whether inhibition of the receptor by
a certain degree, e.g., 90% could be sufficient to protect ex-
perimental animals against sepsis, while the remaining degree,
e.g., 10% of receptor activity, could be enough to mount ade-
quate antiviral and antibacterial responses. Whether a suffi-
ciently strong inhibition of the IFNAR1 will be possible has to
be evaluated first. Inhibition of ligand could be problematic
too, since many type I IFNs may play a role in endotoxemia.
Luckily, the resistance of IFN- deficient mice to endotoxemia
resembles that of IFNAR1 knockouts, indicating that IFN- is
the type I IFN playing the predominant role in endotoxemia.
Moreover, IFN- is the major type I IFN induced by LPS (36),
although IFN-4 was also induced by LPS in macrophages
(39). Furthermore, septic patients may be treated with IFN-
blocking agents over a short time in strictly contained condi-
tions to prevent viral infection.
The second question that needs to be addressed is whether
type I IFNs also play a mediating role in real sepsis and not just
in endotoxemia. To our knowledge, there are no published
studies endorsing this hypothesis in the case of gram-negative
sepsis. However, it was clearly demonstrated that type I IFNs
are essential in the lethal response of mice to gram-positive
Listeria monocytogenes infection, probably because macro-
phages are sensitized to cell death by the production of type I
IFN induced by this organism (75). Although our knowledge of
the role of type I IFNs in endotoxemia indicates that they also
play a mediating role in sepsis, experimental evidence is
needed to confirm this hypothesis. Thus, we should exercise
great caution when depicting IFN- as a possible drug target
for sepsis.
Finally, endotoxemia (and probably sepsis) are not the only
disorders in which type I IFNs play a detrimental role and in
which the type I IFN system should be blocked. Given the
diverse and potent effects of type I IFNs in the innate and
adaptive immune systems, it is not surprising that they play a
pivotal pathogenic role in several autoimmune diseases. In-
creased levels of IFN- in serum were found to correlate with
exacerbation of systemic lupus erythematosus (5, 35) and in-
sulin-dependent diabetes mellitus (16, 74) in humans and ro-
dents, and IFN- overexpression in beta cells at the onset of
diabetes has been reported in human patients (19).
CONCLUSION
Many recent data suggest that type I IFNs and several mol-
ecules involved in inducing them and in responding to them
play essential mediating roles in endotoxemia induced by
gram-negative cell wall components and in several autoim-
mune disorders. These data indicate that key molecules, such
as IFN- and IFNAR1, may be considered as new therapeutic
targets in endotoxemia in experimental animals and sepsis in
human patients, provided that their essential role in antiviral
defense and in activation of the immune system are not com-
promised.
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